Everolimus Stent in Patients With Coronary Artery Disease (CAD)

Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01182649

Acronym

RACES

Enrollment

600

Registered

2010-08-17

Start date

2007-03-31

Completion date

2010-06-30

Last updated

2010-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Coronary Atherosclerosis

Keywords

Drug Eluting Stents, Everolimus Eluting Stent, Coronary Angioplasty

Brief summary

Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients

Detailed description

Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.

Interventions

DEVICEcoronary stent

coronary angioplasty with stent implantation

DEVICEstent

coronary angioplasty with stent implantation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)

Exclusion criteria

* Contraindication to dual antiplatelet therapy for 12 months * Known allergy to sirolimus or everolimus * Major surgical procedure planned within 1 month * History, symptoms, or findings suggestive of aortic dissection. * Participation in other trials * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Target Vessel Revascularization	2 year	Incidence of clinically driven target vessel revascularization at 2 year follow up

Secondary

Measure	Time frame	Description
cardiac death	2 year	incidence of death for cardiac causes at 2 year
non fatal myocardial infarction	2 year	incidence of non fatal Q or non Q wave reinfarction at 2 year
stent thrombosis	2 year	incidence of definite, probable or possible stent thrombosis at 2 year

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026